The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Tegoprubart - kidney transplantation programs | - | 9,394 | - | - |
| Tegoprubart - other development programs | - | 0 | - | - |
| Manufacturing | - | 3,943 | - | - |
| Personnel-related expenses | - | 3,718 | - | - |
| Stock-based compensation | - | 2,465 | - | - |
| Other segment items | - | 7,474 | - | - |
| Other income, net | - | 540 | - | - |
| Change in fair value of warrant liabilities | - | -10,532 | - | - |
| Total operating expenses | -40,586 | - | - | - |
| Loss from operations | 40,586 | - | - | - |
| Other income, net | -2,562 | - | - | - |
| Provision for income taxes | - | 35 | - | - |
| Change in fair value of warrant liabilities | 18,962 | - | - | - |
| Net loss | -39,025 | -10,447 | -17,459 | -17,711 |
| Non-cash lease expense | 83 | 81 | 79 | 77 |
| Accretion of investment discounts | -460 | -321 | -251 | -432 |
| Stock-based compensation | 2,202 | 2,465 | 2,428 | 2,694 |
| Change in fair value of warrant liabilities | 18,962 | -10,532 | -564 | -22,353 |
| Deferred tax provision | - | 5 | - | - |
| Prepaid expenses and other assets | -12 | -701 | -805 | 989 |
| Accounts payable, accrued expenses and other liabilities | -4,300 | 4,038 | 566 | 4,523 |
| Operating lease liabilities | -86 | -81 | -81 | -77 |
| Net cash used in operating activities | -22,612 | -14,091 | -14,477 | -17,713 |
| Purchase of available-for-sale short-term investments | 43,122 | 69,223 | 32,655 | 27,404 |
| Proceeds from maturities of available-for-sale short-term investments | 49,078 | 48,761 | 45,060 | 42,362 |
| Net cash provided by investing activities | 5,956 | -20,462 | 12,405 | 14,958 |
| Proceeds from issuances of common stock and pre-funded warrants, net | - | 53,577 | - | - |
| Proceeds from exercise of stock options | - | 115 | 0 | 0 |
| Net cash provided by financing activities | - | 53,692 | 0 | 0 |
| Net change in cash and cash equivalents | -16,656 | 19,139 | -2,072 | -2,755 |
| Cash and cash equivalents at beginning of period | 22,808 | 3,669 | 20,549 | - |
| Cash and cash equivalents at end of period | 6,152 | 22,808 | 3,669 | - |
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)